Brazil's health regulator Anvisa has approved the first generic semaglutide injection pen, marketed as Ozivy [1, 2].
The approval marks a significant shift in the accessibility of weight-loss and diabetes medications in Brazil. By allowing generic versions of high-demand drugs, the regulator aims to lower costs for patients who previously relied on expensive brand-name options.
The decision follows the expiration of the patent for the original drug Ozempic [2]. This legal change allows other manufacturers to produce the same active ingredient, semaglutide, which is used to treat both type 2 diabetes and obesity.
Reports on the specific scope of the approval vary between sources. One report said that the regulator published the decision on Monday, May 17, 2024 [1], and noted the approval of two pens for diabetes treatment [1]. Another report said the approval was announced on Tuesday, May 26, 2024 [2], focusing on the introduction of the first semaglutide pen [2].
Anvisa's move is expected to increase competition within the Brazilian pharmaceutical market. The introduction of Ozivy provides a direct alternative to the brand-name medication, potentially reducing the price barrier for thousands of citizens requiring long-term metabolic treatment.
Generic medications must demonstrate bioequivalence to the original drug to receive Anvisa's clearance. This ensures that the generic version performs the same therapeutic function as the patented version it replaces.
“Anvisa has approved the first generic semaglutide injection pen, marketed as Ozivy.”
The entry of generic semaglutide into the Brazilian market signals a transition from a monopoly to a competitive pricing environment for GLP-1 receptor agonists. While the original patent protected the profits of the innovator company, the expiration allows for broader public health access. This move may reduce the financial burden on Brazil's healthcare system and individual patients, though it also increases the regulatory burden on Anvisa to monitor the quality and safety of multiple generic manufacturers.
